Novartis Fluad Phase III study meets primary endpoint
The Phase III randomised, blinded, controlled study was conducted at trial sites in Germany and Finland. Novartis said that the study aimed to assess the reactogenicity of the
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.
Shrink said that Stemage software will be launched with StemDisc products for developing intuitive and integrated bio-informatics database to facilitate the acquisition and sharing of three-dimensional (3D) imaging